A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 900 participants.

Also called NCT07421284

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 900 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07421284
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07421284. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-31 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
Condition
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Intervention (Drug)
SYH2053/placebo injection
Lead sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07421284
Content hash
d291488e826211646d18c48b21b688271954e4185d4692d71ea983aacf443bf1